Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023
Helius Medical Technologies (Nasdaq:HSDT) announced that CEO Dane Andreeff and CFO Jeff Mathiesen will present at the Virtual Q1 Investor Summit Microcap Event on January 26, 2023, at 9:30 AM ET. Investors interested in one-on-one meetings can register online. Helius focuses on neurological wellness through non-implantable technologies that enhance the brain's compensation ability and promote neuroplasticity. Their primary product, the Portable Neuromodulation Stimulator (PoNS), is designed for treating gait deficits due to multiple sclerosis and is approved for use in the U.S., Canada, and Australia.
- None.
- None.
NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the Virtual Q1 Investor Summit Microcap Event, as follows:
| Date: Time: Webcast: | Thursday, January 26, 2023 9:30 AM ET Click Here | |
Investors who would like to schedule a 1-on-1 meeting with Helius management can register at Investor Registration.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit ponstherapy.com.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What is the date and time of HSDT's presentation at the Investor Summit?
How can I register for a one-on-one meeting with HSDT management?
What is the Portable Neuromodulation Stimulator (PoNS)?
Where is the PoNS device approved for use?
Who will represent HSDT at the Virtual Q1 Investor Summit?
